These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

102 related items for PubMed ID: 20472597

  • 1. Blood pressure changes in patients with recent-onset rheumatoid arthritis treated with four different treatment strategies: a post hoc analysis from the BeSt trial.
    Klarenbeek NB, van der Kooij SM, Huizinga TJ, Goekoop-Ruiterman YP, Hulsmans HM, van Krugten MV, Speyer I, de Vries-Bouwstra JK, Kerstens PJ, Huizinga TW, Dijkmans BA, Allaart CF.
    Ann Rheum Dis; 2010 Jul; 69(7):1342-5. PubMed ID: 20472597
    [Abstract] [Full Text] [Related]

  • 2. Patient-reported outcomes in a randomized trial comparing four different treatment strategies in recent-onset rheumatoid arthritis.
    van der Kooij SM, de Vries-Bouwstra JK, Goekoop-Ruiterman YP, Ewals JA, Han KH, Hazes JM, Kerstens PJ, Peeters AJ, van Zeben D, Breedveld FC, Huizinga TW, Dijkmans BA, Allaart CF.
    Arthritis Rheum; 2009 Jan 15; 61(1):4-12. PubMed ID: 19116965
    [Abstract] [Full Text] [Related]

  • 3. Treatment of recent-onset rheumatoid arthritis: lessons from the BeSt study.
    Allaart CF, Breedveld FC, Dijkmans BA.
    J Rheumatol Suppl; 2007 Nov 15; 80():25-33. PubMed ID: 17985420
    [Abstract] [Full Text] [Related]

  • 4. Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the BeSt study.
    van den Broek M, Klarenbeek NB, Dirven L, van Schaardenburg D, Hulsmans HM, Kerstens PJ, Huizinga TW, Dijkmans BA, Allaart CF.
    Ann Rheum Dis; 2011 Aug 15; 70(8):1389-94. PubMed ID: 21515916
    [Abstract] [Full Text] [Related]

  • 5. Aiming at low disease activity in rheumatoid arthritis with initial combination therapy or initial monotherapy strategies: the BeSt study.
    Allaart CF, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Breedveld FC, Dijkmans BA, FARR study group.
    Clin Exp Rheumatol; 2006 Aug 15; 24(6 Suppl 43):S-77-82. PubMed ID: 17083767
    [Abstract] [Full Text] [Related]

  • 6. Association of high body mass index with decreased treatment response to combination therapy in recent-onset rheumatoid arthritis patients.
    Heimans L, van den Broek M, le Cessie S, Siegerink B, Riyazi N, Han KH, Kerstens PJ, Huizinga TW, Lems WF, Allaart CF.
    Arthritis Care Res (Hoboken); 2013 Aug 15; 65(8):1235-42. PubMed ID: 23408767
    [Abstract] [Full Text] [Related]

  • 7. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial.
    Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, Brown C, Fraser A, Jarret S, Emery P.
    Arthritis Rheum; 2005 Jan 15; 52(1):27-35. PubMed ID: 15641102
    [Abstract] [Full Text] [Related]

  • 8. Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies.
    de Vries-Bouwstra JK, Goekoop-Ruiterman YP, Verpoort KN, Schreuder GM, Ewals JA, Terwiel JP, Ronday HK, Kerstens PJ, Toes RE, de Vries RR, Breedveld FC, Dijkmans BA, Huizinga TW, Allaart CF.
    Arthritis Rheum; 2008 May 15; 58(5):1293-8. PubMed ID: 18438829
    [Abstract] [Full Text] [Related]

  • 9. Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis.
    Vis M, Nurmohamed MT, Wolbink G, Voskuyl AE, de Koning M, van de Stadt R, Twisk JW, Dijkmans BA, Lems WF.
    J Rheumatol; 2005 Feb 15; 32(2):252-5. PubMed ID: 15693084
    [Abstract] [Full Text] [Related]

  • 10. Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity.
    Vander Cruyssen B, Van Looy S, Wyns B, Westhovens R, Durez P, Van den Bosch F, Mielants H, De Clerck L, Peretz A, Malaise M, Verbruggen L, Vastesaeger N, Geldhof A, Boullart L, De Keyser F.
    Arthritis Res Ther; 2006 Feb 15; 8(4):R112. PubMed ID: 16978395
    [Abstract] [Full Text] [Related]

  • 11. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab.
    Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T.
    Arthritis Rheum; 2006 Dec 15; 54(12):3782-9. PubMed ID: 17133559
    [Abstract] [Full Text] [Related]

  • 12. The effect of infliximab on bone metabolism markers in patients with rheumatoid arthritis.
    Torikai E, Kageyama Y, Takahashi M, Suzuki M, Ichikawa T, Nagafusa T, Nagano A.
    Rheumatology (Oxford); 2006 Jun 15; 45(6):761-4. PubMed ID: 16436492
    [Abstract] [Full Text] [Related]

  • 13. Treatment with infliximab plus methotrexate improves anemia in patients with rheumatoid arthritis independent of improvement in other clinical outcome measures-a pooled analysis from three large, multicenter, double-blind, randomized clinical trials.
    Doyle MK, Rahman MU, Han C, Han J, Giles J, Bingham CO, Bathon J.
    Semin Arthritis Rheum; 2009 Oct 15; 39(2):123-31. PubMed ID: 18823645
    [Abstract] [Full Text] [Related]

  • 14. Infliximab improves vascular stiffness in patients with rheumatoid arthritis.
    Wong M, Oakley SP, Young L, Jiang BY, Wierzbicki A, Panayi G, Chowienczyk P, Kirkham B.
    Ann Rheum Dis; 2009 Aug 15; 68(8):1277-84. PubMed ID: 18930987
    [Abstract] [Full Text] [Related]

  • 15. Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis.
    Shergy WJ, Isern RA, Cooley DA, Harshbarger JL, Huffstutter JE, Hughes GM, Spencer-Smith EA, Goldman AL, Roth SH, Toder JS, Warner D, Quinn A, Keenan GF, Schaible TF, PROMPT Study Group. Profiling Remicade Onset with MTX in a Prospective Trial.
    J Rheumatol; 2002 Apr 15; 29(4):667-77. PubMed ID: 11950005
    [Abstract] [Full Text] [Related]

  • 16. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL, Watson KD, Silman AJ, Symmons DP, British Society for Rheumatology Biologics Register.
    Rheumatology (Oxford); 2006 Dec 15; 45(12):1558-65. PubMed ID: 16705046
    [Abstract] [Full Text] [Related]

  • 17. A comparison of response criteria to evaluate therapeutic response in patients with juvenile idiopathic arthritis treated with methotrexate and/or anti-tumor necrosis factor alpha agents.
    Lurati A, Pontikaki I, Teruzzi B, Desiati F, Gerloni V, Gattinara M, Cimaz R, Fantini F.
    Arthritis Rheum; 2006 May 15; 54(5):1602-7. PubMed ID: 16646003
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Evolution of antinuclear antibodies and clinical patterns in patients with active rheumatoid arthritis with longterm infliximab therapy.
    Comby E, Tanaff P, Mariotte D, Costentin-Pignol V, Marcelli C, Ballet JJ.
    J Rheumatol; 2006 Jan 15; 33(1):24-30. PubMed ID: 16395746
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.